Tag: research and development
Pfizer Shrinks Its Drug Pipeline Amid R&D Cuts
by Melly Alazraki on Mar.01, 2011, under Towing
In an update Tuesday, Pfizer said it is discontinuing 15 of the projects in its development pipeline. The news comes a month after the world’s largest pharmaceutical company announced large research and development cuts were on the way.
Continue reading Pfizer Shrinks Its Drug Pipeline Amid R&D Cuts
Pfizer Shrinks Its Drug Pipeline Amid R&D Cuts originally appeared on DailyFinance on Tue, 01 Mar 2011 20:00:00.
Filed Under: Health Care, Pfizer
The 10 Biggest-Selling Drugs That Are About to Lose Their Patent
by Melly Alazraki on Feb.27, 2011, under Towing
The pharmaceutical industry is ready to fall off a cliff — a “patent cliff.” Over the next few years, some of the world’s most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from drugmakers’ bottom lines.
Continue reading The 10 Biggest-Selling Drugs That Are About to Lose Their Patent
The 10 Biggest-Selling Drugs That Are About to Lose Their Patent originally appeared on DailyFinance on Sun, 27 Feb 2011 08:00:00.
Filed Under: Company News, Investing, Health Care, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Merck, Eli Lilly, Astrazeneca
Pfizer Joins Other Pharmas in Giving a Cautious Outlook
by Melly Alazraki on Feb.01, 2011, under Towing
Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What’s ahead for the world’s biggest drugmaker:
Continue reading Pfizer Joins Other Pharmas in Giving a Cautious Outlook
Pfizer Joins Other Pharmas in Giving a Cautious Outlook originally appeared on DailyFinance on Tue, 01 Feb 2011 15:41:00.
Filed Under: Company News, Health Care, Earnings, Pfizer, Bristol-Myers Squibb, Novartis, Eli Lilly, Astrazeneca
Inside Wall Street: This Tiny Biotech Has Pfizer as a Big Backer
by Gene Marcial on Jan.24, 2011, under Towing
Lpath focuses on developing therapeutics that target bioactive lipids for treating a range of human diseases, including cancer and diseases that cause blindness. Its promising drugs have attracted attention — and lots of money — from Pfizer. More of both could be coming.
Continue reading Inside Wall Street: This Tiny Biotech Has Pfizer as a Big Backer
Inside Wall Street: This Tiny Biotech Has Pfizer as a Big Backer originally appeared on DailyFinance on Mon, 24 Jan 2011 07:30:00.
Filed Under: Company News, Columns, Investing, Health Care, Pfizer, Stock Picks
The Autism Study Fraud’s Impact on Scientific Research
by Bruce Kennedy on Jan.12, 2011, under Towing
Aside from the embarrassment, researchers know deceptions like the autism research fraud can have much larger consequences, both for the parents of autistic children and for the future of their studies. Says one prominent scientist: “It taints a lot of very good work that goes on.”
Continue reading The Autism Study Fraud’s Impact on Scientific Research
The Autism Study Fraud’s Impact on Scientific Research originally appeared on DailyFinance on Wed, 12 Jan 2011 15:30:00.
Filed Under: Health Care
-
You Can Reach Us At:
For All Of Your Towing and Recovery Needs.
Tele: (847) 587-6076
Fax: (847) 587-8610 Some Of Our Pics
